redalpine has led Helical’s $10 million seed round, backing a company at the intersection of AI, biology and drug discovery. Helical is building a platform designed to make biological foundation models usable in real pharmaceutical R&D workflows, and is already collaborating with multiple top-20 pharma companies, including a public partnership with Pfizer.

The deal highlights redalpine’s appetite for technically ambitious companies using AI to solve complex scientific problems with real commercial potential. As Helical scales its platform and expands deeper into pharma, the investment positions redalpine at the forefront of one of the most promising areas in life sciences innovation.

https://thenextweb.com/news/helical-10m-seed-bio-foundation-models-pharma-ai